Life-sciences-tools and diagnostics names have been the toughest corner of healthcare since late 2024 — and Bio-Rad is now the latest cautionary tale. Bio-Rad stock trades near $295, and we rate it a wait-for-a-pullback Hold with a $320 average analyst price target, an analytical view supported by management's decision to lower full-year 2026 guidance after Q1 net sales of $592.1 million grew just 1.1% year over year. The Middle East conflict shaved $11 million from Diagnostics quarterly revenue and is now expected to remain a significant full-year headwind. Academic demand is constrained in the Americas as funding pressures bite. The bio-rad stock setup is one of the clearest examples of a quality franchise that needs a better entry point before the catalyst clock starts ticking again. This bio-rad stock price deep dive walks through the cut guidance, valuation, the diagnostics-vs-life-science segment split, and where the analyst-target distribution actually breaks.
Key Bio-Rad Stock Data
| Metric | Value |
| Current Price | ~$295.00 |
| 52-Week Range | $240.00 – $390.00 |
| Market Cap | ~$8.3B |
| Q1 2026 Revenue | $592.1M (+1.1% YoY) |
| Q1 2026 FCF | $78.1M |
| 2026 Revenue Outlook | -3.0% to +0.5% (cut) |
| 2026 Op Margin Outlook | 10.0% – 12.0% (cut) |
| Analyst Consensus | Hold / Buy (mixed) |
| Average Price Target | $320.00 |
Table of Contents
- Key Bio-Rad Stock Data
- Bio-Rad Stock Key Takeaways
- What Is Bio-Rad (BIO)?
- Bio-Rad Stock Q1 2026 Earnings and Cut Guidance
- Bio-Rad Stock Valuation Analysis
- Bullish and Bearish Analyst Opinions on Bio-Rad Laboratories
- BIO Analyst Targets and Stock Price Forecast
- Bio-Rad Stock: Life Science vs Diagnostics Segment Split
- BIO Stock FAQs
Bio-Rad Stock Key Takeaways
- Price and verdict. Bio-Rad stock trades near $295 with a mixed Hold/Buy consensus and a $320 average 12-month target — about 8% headline upside but with material left-tail risk.
- Headline stat. Q1 2026 net sales of $592.1 million grew just 1.1% YoY; the Middle East conflict reduced Diagnostics revenue by $11 million and is expected to remain a significant full-year headwind.
- Bull case. The Sartorius equity stake remains a meaningful asset on the balance sheet; FCF generation of $78.1M in Q1 is durable; the diagnostics franchise eventually recovers when geopolitical pressure normalises.
- Bear case. Lowered 2026 guidance — revenue band now -3.0% to +0.5% with operating margin 10–12% (down from 12–12.5%); academic funding constraints could persist for multiple quarters.
- What we'd watch. Diagnostics revenue trajectory through 2026, academic-funding restoration in the Americas, and any commentary on Sartorius stake monetisation.
What Is Bio-Rad (BIO)?
Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global manufacturer of life-science research products and clinical-diagnostics tools. Founded in 1952 and headquartered in Hercules, California, Bio-Rad operates through two reporting segments: Life Science (research reagents, instruments for protein and gene analysis, droplet digital PCR systems, and food-safety testing) and Clinical Diagnostics (immunohematology, quality controls, blood typing, and infectious-disease testing). The company sells into academic research labs, hospitals, biotech and pharma firms, blood-bank operations, and food-safety testing networks across more than 30 countries.
The Bio-Rad stock investment thesis carries two distinct layers. The operating business is a high-quality but slow-growth life-sciences-tools franchise that throws off consistent free cash flow even in down years — Q1 2026 generated $78.1 million in free cash flow despite weak top-line growth. Separately, Bio-Rad holds a substantial equity stake in Sartorius AG, the German bioprocessing equipment maker, which adds a meaningful non-operating asset to the balance sheet. The combined value structure is one reason analyst targets cluster well above the current trading price even when fundamentals look soft. Compared with adjacent life-sciences-tools compounders like Abbott Laboratories stock price or Edwards Lifesciences stock price, BIO offers exposure to a quieter slice of the tools market with a unique sum-of-parts overlay.
The Sartorius equity stake is worth a closer look because it's the single largest non-operating asset on the Bio-Rad balance sheet. Bio-Rad inherited the position through its 2013 acquisition of Sartorius shares, and it has held roughly 33% to 37% of Sartorius' vorzugsaktien (preferred shares) ever since. The position has fluctuated meaningfully in value alongside Sartorius' own share price, which itself has been pressured by the broader bioprocessing slowdown of 2023-2025. If Sartorius shares recover as biopharma capital spending normalises, the stake's contribution to BIO's sum-of-parts value increases mechanically — without Bio-Rad management needing to take any action. That optionality is what bull-case targets are explicitly modelling. For context on the broader biopharma capital-spending cycle, investors can layer in a watchlist against Amgen stock price for end-customer demand signals.
Bio-Rad Stock Q1 2026 Earnings and Cut Guidance
The Q1 2026 print was a guide-down moment. Net sales grew 1.1% year over year to $592.1 million — within management's prior revenue guidance band but at the low end. The Middle East conflict reduced Diagnostics quarterly revenue by approximately $11 million, and management explicitly flagged that this drag would persist as a significant headwind for revenue and margin through full-year 2026. Academic demand, particularly in the Americas, remained constrained because of funding changes that have rippled through the broader life-sciences research budget.
Management responded by cutting full-year 2026 guidance. The revised non-GAAP currency-neutral revenue outlook now spans negative 3.0% to positive 0.5% — essentially flat to slightly down — while the non-GAAP operating margin outlook was reduced to 10.0% to 12.0%, down from the prior 12.0% to 12.5% band. The combination of slower revenue and tighter margins implies a meaningful step-down in 2026 EPS versus consensus expectations heading into the quarter. The free-cash-flow profile remained intact, with $108.1 million in net cash from operations and $78.1 million in free cash flow — a positive signal that the underlying business quality has not deteriorated, even though the headline growth and margin trajectory has. For bio-rad stock investors, the Q1 print is precisely the kind of news that flips the trade from chase-the-rebound to wait-for-a-pullback.
Bio-Rad Stock Valuation Analysis
The bio-rad stock valuation discussion centres on whether the Sartorius equity stake plus the slow-growth tools business is worth a premium to the current $295 print. The table below frames the spread.
| Framework | Multiple/Estimate | Implied Price | Comment |
| Tools-segment standalone (P/E) | ~20x | ~$240 | Slow growth, modest margin |
| Current trading multiple | ~25x | ~$295 | Reflects part of Sartorius value |
| Sum-of-parts (mid-case) | — | ~$320 | Adds Sartorius stake at market |
| Sum-of-parts (bull case) | — | ~$390 | Sartorius recovery plus tools rebound |
| FCF yield | ~3.8% | — | Above tools-peer median |
The sum-of-parts framework anchors the $320 average analyst target. If you separate the Sartorius equity stake (worth roughly $1.5–2 billion depending on Sartorius' trading price) and value the Bio-Rad tools business on its own merits, the math comfortably gets you above $295. The bull case at $390 requires both the Sartorius stake to recover meaningfully from its 2024-2025 drawdown and the diagnostics franchise to absorb the Middle East drag without further negative revisions. The bear case at $240 requires another guidance cut plus continued Sartorius weakness. For a complete bio-rad stock price analysis, model the Sartorius stake as a separate line item; every 10% move in Sartorius shares moves BIO fair value by roughly $5–7.
Bullish and Bearish Analyst Opinions on Bio-Rad Laboratories
The analyst community on bio-rad stock is split. Some datasets show 4 analysts publishing with a Buy consensus and an average target of $339.75; others show 7 analysts with a neutral consensus and a median target of $305 (4 Hold, 0 Buy, 0 Sell). The disagreement is exactly what creates the wait-for-a-pullback opportunity.
| Stance | Desk Profile | Rating | Target | Argument |
| Most Bullish | Street High | Buy | $409 | Sum-of-parts value plus Sartorius recovery |
| Bullish | 4-Analyst Avg | Buy | $339.75 | Sustained FCF plus diagnostics rebound |
| Consensus | 7-Analyst Median | Hold | $305 | Lowered guidance warrants tempered expectations |
| Cautious | WallStreetZen | Hold | $320 | Mixed signals balance against quality balance sheet |
| Most Bearish | Street Low | Hold | $280 | Continued Middle East drag plus academic funding pressure |
The bullish view focuses on three pillars: the sum-of-parts math (Sartorius stake plus standalone tools value) supports a meaningful premium to current price, free-cash-flow generation has held up despite the revenue weakness, and the diagnostics franchise is structurally high-quality even if the Middle East drag persists. The bearish view focuses on near-term execution: lowered guidance signals that the operating environment is worse than previously modeled, and academic funding constraints may take multiple quarters to normalise. Our read: the bull case is mechanically valid over a 12- to 18-month horizon, but the entry price matters more than usual. Waiting for a $285 or lower print improves the asymmetric reward by tightening downside while preserving most of the upside.
BIO Analyst Targets and Stock Price Forecast
The published 12-month analyst targets on BIO stock span $280 (low) to $409 (high), with the consensus average between $305 and $339.75 across data sources. We anchor on $320 as the most credible blend. From the current $295 print, the average implies roughly 8% upside; the high target implies 39% upside; the low target implies 5% downside — a moderately constructive but range-bound distribution.
Our base-case BIO stock price forecast for the next 12 months sits at $315 — modest re-rate to slightly above the analyst median. The bull case at $360+ requires the Sartorius stake to recover meaningfully (roughly a 25%+ move in Sartorius shares) plus diagnostics revenue to absorb the Middle East drag without further negative revisions. The bear case at $260–$275 requires another guidance cut or sustained Sartorius weakness. Investors building a BIO position should consider scaling in below $285 rather than chasing strength above $310 — exactly the "wait for a pullback" framing that the current dispersion supports.
Bio-Rad Stock: Life Science vs Diagnostics Segment Split
The two operating segments inside Bio-Rad face different sets of headwinds. Life Science (research reagents, instruments, droplet digital PCR) is exposed to academic funding cycles. The combination of US federal-research budget pressure plus international academic constraints has compressed near-term demand, particularly in the Americas. The segment's long-term thesis (research-grade equipment standardisation, ddPCR adoption in clinical applications, food-safety testing expansion) remains intact, but the timing of any rebound depends on academic funding restoration.
Clinical Diagnostics (blood typing, immunohematology, quality controls, infectious-disease testing) faces a different challenge: the Middle East conflict directly reduced Q1 revenue by $11 million and is now embedded in management's full-year guidance as a significant headwind. Geopolitical risk of this kind is notoriously hard to model, but the underlying franchise is structurally defensive — blood-bank and quality-control products are essential operating inputs for hospitals, which tend to keep buying through cycles. Once the conflict-related drag normalises, the diagnostics franchise should return to its long-term mid-single-digit growth profile. The combination of two structurally different headwinds is exactly why management cut full-year guidance and why the bio-rad stock price has lagged broader healthcare-tools indexes.
One technical point worth flagging: the segment mix matters for margin analysis. Diagnostics historically carries higher operating margins than Life Science, so when Diagnostics revenue weakens disproportionately (as it did in Q1 because of the Middle East drag), the overall company operating margin compresses faster than the revenue trajectory alone would suggest. That dynamic explains why management cut the margin range by roughly 100 basis points even though the revenue cut was smaller. For modelling purposes, the swing variable is whether Diagnostics can return to its trend mid-single-digit growth rate; if it does, both top-line and margin recover together. If Diagnostics stays under pressure, the bio-rad stock will likely remain range-bound through the back half of 2026.
BIO Stock FAQs
Is BIO a good stock to buy in 2026?
For long-horizon investors comfortable with multi-quarter holding periods, bio-rad stock at $295 is best framed as a wait-for-a-pullback Buy rather than a chase-the-breakout call. The $320 average analyst target implies modest 8% upside, but the Q1 guide-down creates near-term sentiment overhang. Scaling in below $285 improves the asymmetric reward while preserving most of the sum-of-parts upside.
What are the bullish and bearish analyst opinions on Bio-Rad Laboratories stock?
The nuance is that analyst opinion is genuinely split. Bullish desks anchor on the sum-of-parts value plus Sartorius stake, with targets up to $409. The neutral consensus at $305 reflects the cut 2026 guidance. The bearish $280 target reflects continued Middle East drag plus academic funding pressure. The dispersion itself is the signal: this is a name where entry-price discipline matters more than usual.
What did Bio-Rad report in Q1 2026?
Bio-Rad reported Q1 2026 net sales of $592.1 million (up 1.1% YoY) with free cash flow of $78.1 million. The Middle East conflict reduced Diagnostics quarterly revenue by $11 million. Management cut full-year 2026 guidance to non-GAAP currency-neutral revenue between -3.0% and +0.5% growth, with operating margin guidance reduced to 10–12% from the prior 12–12.5% range.
What is the Bio-Rad stock price forecast for 2026?
Our 12-month base-case BIO stock price forecast is $315 — a modest re-rate from the current $295. The bull case at $360+ requires a Sartorius recovery plus diagnostics stabilisation. The bear case at $260–$275 requires another guidance cut. The high analyst target is $409; the low is $280.
Why did Bio-Rad lower 2026 guidance?
Bio-Rad lowered guidance because of two persistent headwinds disclosed in Q1: the Middle East conflict reduced Diagnostics revenue by $11 million in the quarter and is expected to remain a significant full-year headwind, and academic demand in the Americas is constrained by funding changes. Combined, those headwinds compress both top-line growth and operating margin, leading management to cut the revenue range to -3.0% to +0.5% and the margin range to 10–12% from prior 12–12.5%.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.
